scholarly journals In Vitro Activities of Eravacycline and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas

2020 ◽  
Vol 64 (8) ◽  
Author(s):  
Ken B. Waites ◽  
Donna M. Crabb ◽  
Li Xiao ◽  
Lynn B. Duffy ◽  
Sixto M. Leal
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Antimicrobial Agents ◽  
Susceptibility Testing ◽  
Ureaplasma Urealyticum ◽  
Mycoplasma Hominis ◽  
Mycoplasma Genitalium ◽  
Content Type ◽  
Ureaplasma Parvum

ABSTRACT We performed in vitro susceptibility testing for eravacycline in comparison to 4 other antimicrobials against 10 Mycoplasma genitalium, 40 Mycoplasma hominis, 44 Mycoplasma pneumoniae, 20 Ureaplasma parvum, and 20 Ureaplasma urealyticum isolates. All eravacycline MICs were ≤0.25 μg/ml, except that for one isolate of M. genitalium, for which the MIC was 2 μg/ml. Eravacycline was markedly more potent than tetracycline, azithromycin, moxifloxacin, and clindamycin against all isolates tested, which included 37 macrolide, tetracycline, and/or fluoroquinolone-resistant organisms.

scholarly journals In Vitro Activities of Gepotidacin (GSK2140944) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas

2017 ◽  
Vol 61 (10) ◽  
Author(s):  
Ken B. Waites ◽  
Donna M. Crabb ◽  
Li Xiao ◽  
Lynn B. Duffy
Keyword(s):  
Topoisomerase Ii ◽  
Antimicrobial Agents ◽  
Ureaplasma Urealyticum ◽  
Mycoplasma Hominis ◽  
Mycoplasma Genitalium ◽  
Content Type ◽  
Topoisomerase Ii Inhibitor ◽  
Ureaplasma Parvum ◽  
Type Strains

ABSTRACTGepotidacin, a novel first-in-class triazaacenaphthylene topoisomerase II inhibitor, was tested against 85 type strains and clinical isolates ofMycoplasma pneumoniae,Mycoplasma hominis,Mycoplasma genitalium,Ureaplasma parvum, andUreaplasma urealyticumin comparison to levofloxacin, moxifloxacin, azithromycin or clindamycin, and tetracycline. Gepotidacin MIC90s (μg/ml) were 0.125 (M. pneumoniae), 0.032 (M. genitalium), 2 (M. hominis), and 8 (Ureaplasmaspecies). Gepotidacin activity was not affected by resistance to fluoroquinolones, tetracyclines, or macrolides in the strains tested. Gepotidacin merits further study for treating infections caused by these organisms.

scholarly journals Comparative In Vitro Activities of the Investigational Fluoroquinolone DC-159a and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas

2008 ◽  
Vol 52 (10) ◽  
pp. 3776-3778 ◽  
Author(s):  
Ken B. Waites ◽  
Donna M. Crabb ◽  
Lynn B. Duffy
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Antimicrobial Agents ◽  
Mycoplasma Hominis ◽  
Mycoplasma Genitalium ◽  
The Other ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Mycoplasma Fermentans

ABSTRACT The in vitro susceptibilities of 151 unique clinical isolates of Mycoplasma pneumoniae, Mycoplasma hominis, Mycoplasma fermentans, Mycoplasma genitalium, and Ureaplasma species to DC-159a, an investigational fluoroquinolone, in comparison with those to other agents were determined. Macrolides were the most active agents against M. pneumoniae and M. genitalium, whereas clindamycin was most active against M. hominis. DC-159a MICs were ≤0.5 μg/ml for all Mycoplasma species and ≤4 μg/ml for ureaplasmas. DC-159a was the most active fluoroquinolone tested against M. pneumoniae and M. fermentans, and it was second to moxifloxacin against the other species. It was bactericidal against 10 M. pneumoniae isolates and demonstrated killing of ≥99.9% of the inoculum at 24 h for 2 isolates. The excellent in vitro activity of DC-159a demonstrates its potential for use in the treatment of infections due to mycoplasmas and ureaplasmas.

scholarly journals In VitroActivities of the Benzoquinolizine Fluoroquinolone Levonadifloxacin (WCK 771) and Other Antimicrobial Agents against Mycoplasmas and Ureaplasmas in Humans, Including Isolates with Defined Resistance Mechanisms

2018 ◽  
Vol 62 (11) ◽  
Author(s):  
G. Xue ◽  
D. M. Crabb ◽  
L. Xiao ◽  
Y. Liu ◽  
K. B. Waites
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Antimicrobial Agents ◽  
Mycoplasma Hominis ◽  
Mycoplasma Genitalium ◽  
Resistance Mechanisms ◽  
Clinical Isolates ◽  
Content Type ◽  
Type Strains

ABSTRACTLevonadifloxacin (WCK 771) was evaluated against 68 type strains and clinical isolates ofMycoplasma genitalium,Mycoplasma hominis,Mycoplasma pneumoniae, andUreaplasmaspp. in comparison with moxifloxacin, levofloxacin, tetracycline, and azithromycin or clindamycin. Levonadifloxacin MICs were ≤0.5 μg/ml forM. genitalium. MIC90s were 1 μg/ml forM. hominis, 0.125 μg/ml forM. pneumoniae, and 2 μg/ml forUreaplasmaspp. Levonadifloxacin merits further study for treating infections caused by these organisms.

Negonorėjiniai uretritai: etiopatogenezė, klinikos, diagnostikos ir gydymo savitumai

2021 ◽  
Vol 25 (4) ◽  
pp. 259-264
Author(s):  
Simona Žilinskienė ◽  
Arūnas Petkevičius
Keyword(s):  
Chlamydia Trachomatis ◽  
Ureaplasma Urealyticum ◽  
Mycoplasma Hominis ◽  
Mycoplasma Genitalium ◽  
Gardnerella Vaginalis ◽  
Ureaplasma Parvum

Negonorėjinis uretritas (NGU) yra dažniausia vyrų lytinių takų liga. Mokslinių tyrimų rezultatais pagrįsta, kad pagrindiniai sukėlėjai yra Chlamydia trachomatis, Mycoplasma genitalium, Ureaplasma urealyticum. Įdiegus pažangius molekulinės diagnostikos metodus, dažnai šlaplės mikrofloroje randama Mycoplasma hominis, Ureaplasma parvum, Gardnerella vaginalis ir kitų saprofitinių mikroorganizmų, kurių svarba uretritų etiopatogenezėje yra prieštaringa ir iki galo neišaiškinta. Negydytas vyrų uretritas gali sukelti sutrikimų, susijusių su reprodukcine bei lytine funkcija, ir yra viena iš pagrindinių nevaisingumo priežasčių. Šio straipsnio tikslas yra, apžvelgus mokslinę literatūrą, išanalizuoti vyrų NGU epidemiologiją, priežastis, diagnostikos ir gydymo galimybes.

scholarly journals Molecular epidemiology of non-viral sexually transmitted infections in the central Alpine province of Bolzano, northern Italy from April 2016 to March 2017

2018 ◽  
Vol 33 (1) ◽  
Author(s):  
Richard Aschbacher ◽  
Francesca Romagnoli ◽  
Elisa Masi ◽  
Valentina Pasquetto ◽  
Franco Perino ◽  
...  
Keyword(s):  
Molecular Epidemiology ◽  
Trichomonas Vaginalis ◽  
Ureaplasma Urealyticum ◽  
Mycoplasma Hominis ◽  
Mycoplasma Genitalium ◽  
Northern Italy ◽  
Sexually Transmitted ◽  
Ureaplasma Parvum ◽  
One Year ◽  
The One

Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Ureaplasma parvum, Ureaplasma urealyticum, Mycoplasma hominis and Mycoplasma genitalium are established or presumed as (??) STI pathogens. The present study aims  at ng describing the one-year molecular epidemiology of these seven pathogens in the Province of Bolzano, Northern Italy. From April 2016 to March 2017, a total of  2,949 patients, mainly females, were enrolled and 3,427 urine, vaginal, endocervical and/or urethral samples were subjected to simultaneous analysis of the seven pathogens by means of Real Time Polymerase Chain Reaction (AnyplexTM II STI-7 Detection Kit Seegene, Seoul, Korea). At least one of the seven microorganisms was detected in 40.7% of patients, with an uneven distribution: 43.1% in females (F) and 29.8% (p<0.001) in males (M). The prevalence of microorganisms was as follows: 30.3% U. parvum (F: 35.6%, M: 8.3%), 6.9% U. urealyticum (F: 6.8%, M: 7.0%), 4.9% M. hominis (F: 5.4%, M: 2.3%), 4.9% C. trachomatis (F: 3.4%, M: 11.4%), 1.1% M. genitalium (F: 1.0%, M: 1.2%), 1.2% N. gonorrhoeae (F: 0.17%, M: 5.6%) and 0.40% T. vaginalis (F: 0.38%, M: 0.53%). Mixed infections were detected in 7.4% of patients. The highest prevalence was observed for U. parvum, followed by U. urealyticum and M. hominis and a significant  presence of multi-pathogen infections was registered.

scholarly journals Comparative In Vitro Susceptibilities of Human Mycoplasmas and Ureaplasmas to a New Investigational Ketolide, CEM-101

2009 ◽  
Vol 53 (5) ◽  
pp. 2139-2141 ◽  
Author(s):  
Ken B. Waites ◽  
D. M. Crabb ◽  
Lynn B. Duffy
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Mycoplasma Hominis ◽  
Mycoplasma Genitalium ◽  
Mycoplasma Fermentans

ABSTRACT MICs were determined for an investigational ketolide, CEM-101, and azithromycin, telithromycin, doxycycline, levofloxacin, clindamycin, and linezolid against 36 Mycoplasma pneumoniae, 5 Mycoplasma genitalium, 13 Mycoplasma hominis, 15 Mycoplasma fermentans, and 20 Ureaplasma isolates. All isolates, including two macrolide-resistant M. pneumoniae isolates, were inhibited by CEM-101 at ≤0.5 μg/ml, making CEM-101 the most potent compound tested.

Sign in / Sign up

Export Citation Format

Share Document